Literature DB >> 14990981

Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma.

Daniel J Brat1, Erwin G Van Meir.   

Abstract

Glioblastoma (GBM) has explosive biologic properties with rapid clinical progression leading to death. Its distinguishing pathologic features, necrosis with surrounding pseudopalisades and microvascular hyperplasia, are believed to be instrumental to its accelerated growth. Microvascular hyperplasia arises in response to the secretion of proangiogenic factors by hypoxic pseudopalisades and allows for peripheral neoplastic expansion. Mechanisms underlying necrosis and hypoxia remain obscure, but vaso-occlusive and prothrombotic contributions could be substantial. Recent investigations on the origin of pseudopalisades suggest that this morphologic phenomenon is created by a tumor cell population actively migrating away from a central hypoxic region and that, in at least a significant subset, hypoxia-induced migration appears due to vaso-occlusion caused by intravascular thrombosis. Both vascular endothelial growth factor induced vascular permeability to plasma coagulation factors and the increased neoplastic expression of tissue factor likely contribute to a prothrombotic state favoring intravascular thrombosis. In addition to prothrombotic mechanisms, vaso-occlusion could also result from angiopoietin-2-mediated endothelial cell apoptosis and vascular regression, which follows neoplastic co-option of native vessels in animal models of gliomas. Vaso-occlusive and prothrombotic mechanisms in GBM could readily explain the presence of pseudopalisades and coagulative necrosis in tissue sections, the emergence of central contrast enhancement and its rapid peripheral expansion on neuroimaging, and the dramatic shift to an accelerated rate of clinical progression. Since the hypoxic induction of angiogenesis appears to support further neoplastic growth, therapeutic targeting of the underlying vascular pathology and thrombosis could provide a new means to prolong time to progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990981     DOI: 10.1038/labinvest.3700070

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  116 in total

1.  Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI.

Authors:  Matthew D Budde; Eric Gold; E Kay Jordan; Joseph A Frank
Journal:  Clin Exp Metastasis       Date:  2011-11-01       Impact factor: 5.150

2.  Nature versus nurture in glioblastoma: microenvironment and genetics can both drive mesenchymal transcriptional signature.

Authors:  Brent A Orr; Charles G Eberhart
Journal:  Am J Pathol       Date:  2012-03-23       Impact factor: 4.307

3.  Expression of coagulation factors and their receptors in tumor tissue and coagulation factor upregulation in peripheral blood of patients with cerebral carcinoma metastases.

Authors:  Jan Walter; Linn L Handel; Michael Brodhun; Denise van Rossum; Uwe-Karsten Hanisch; Lutz Liebmann; Frank Heppner; Roland Goldbrunner; Arend Koch; Susanne A Kuhn
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-08       Impact factor: 4.553

4.  Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.

Authors:  B R Achyut; Adarsh Shankar; A S M Iskander; Roxan Ara; Kartik Angara; Peng Zeng; Robert A Knight; Alfonso G Scicli; Ali S Arbab
Journal:  Cancer Lett       Date:  2015-09-21       Impact factor: 8.679

Review 5.  Neuropathology for the neuroradiologist: palisades and pseudopalisades.

Authors:  F J Wippold; M Lämmle; F Anatelli; J Lennerz; A Perry
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

6.  Combined local blood-brain barrier opening and systemic methotrexate for the treatment of brain tumors.

Authors:  Itzik Cooper; David Last; David Guez; Shirley Sharabi; Shirin Elhaik Goldman; Irit Lubitz; Dianne Daniels; Sharona Salomon; Gregory Tamar; Tzur Tamir; Ronni Mardor; Mati Fridkin; Yoram Shechter; Yael Mardor
Journal:  J Cereb Blood Flow Metab       Date:  2015-02-11       Impact factor: 6.200

7.  Derived vascular endothelial cells induced by mucoepidermoid carcinoma cells: 3-dimensional collagen matrix model.

Authors:  Sen Yang; Li-juan Guo; Qing-hong Gao; Ming Xuan; Ke Tan; Qiang Zhang; Yu-ming Wen; Chang-mei Wang; Xiu-fa Tang; Xiao-yi Wang
Journal:  J Zhejiang Univ Sci B       Date:  2010-10       Impact factor: 3.066

8.  Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma.

Authors:  Adarsh Shankar; Meenu Jain; Mei Jing Lim; Kartik Angara; Peng Zeng; Syed A Arbab; Asm Iskander; Roxan Ara; Ali S Arbab; Bhagelu R Achyut
Journal:  J Cancer Sci Ther       Date:  2016-07-15

9.  Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations.

Authors:  Nathalie Magnus; Delphine Garnier; Brian Meehan; Serge McGraw; Tae Hoon Lee; Maxime Caron; Guillaume Bourque; Chloe Milsom; Nada Jabado; Jacquetta Trasler; Rafal Pawlinski; Nigel Mackman; Janusz Rak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

10.  PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo.

Authors:  R Auvergne; C Wu; A Connell; S Au; A Cornwell; M Osipovitch; A Benraiss; S Dangelmajer; H Guerrero-Cazares; A Quinones-Hinojosa; S A Goldman
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.